Highlights of QBL subsidiary on MMJ DEVELOPMENT.
Post# of 63
(Total Views: 378)
Posted On: 05/01/2018 8:09:43 AM
Highlights of QBL subsidiary on MMJ DEVELOPMENT.
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
See QBL-board and website;https://www.queenslandbauxite.com/
https://www.queenslandbauxite.com/
Read More: https://investorshangout.com/post/view?id=502...z5EFdO6Ii8
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
See QBL-board and website;https://www.queenslandbauxite.com/
https://www.queenslandbauxite.com/
Read More: https://investorshangout.com/post/view?id=502...z5EFdO6Ii8
(0)
(0)
Robert
Scroll down for more posts ▼